Contact us to find out if we have the data you need. Having offices around the globe, we are open 24 hours a day, 5 days a week with multiple language support. Please visit our Contact page to see which office is open right now!

Overview Introduction Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to g more…

Overview Introduction Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The s more…

SMOKING CESSATION IS AN increasingly important area of focus for pharmaceutical companies, healthcare entities and governments. There are 1.4 billion smokers in the world, and more…

Introduction A poorly understood, complex disease that involves a number of neurotransmitters, bipolar disorder presents several challenges for pharmaceutical companies more…

Overview Introduction Datamonitor believes that companies developing pipeline drugs for the depression market should concentrate resources on targeting third-line depression p more…

Introduction Compared with many other disease areas (e.g., cancer, immune diseases), the costs of drug therapy for psychiatric disorders are relatively modest. However, the more…

A comprehensive examination of 6 major CNS therapy areas: neurodegenerative disorders, multiple sclerosis, ADHD, depression, sleep disorders and schizophrenia. The report more…

Current therapies for neurodegenerative and psychiatric diseases leave much to be desired. Alzheimer's and Parkinson's diseases are an increasing burden on the health care more…

Overview Introduction Stimulated by sales of atypical antipsychotics for bipolar depression, and despite the launch of generic risperidone, the global bipolar disorder market more…

Introduction Deep brain stimulation (DBS) is currently approved only to treat Parkinson's disease and Parkinson-like symptoms; however, clinical trials are under way for DBS more…

Sleep disorders affect more than 200 million people worldwide. It is generally accepted that insufficient sleep contributes significantly to automobile accidents and more…

This Frost & Sullivan research service titled European Antidepressants Markets provides a detailed analysis of the antidepressants markets, with a description of key market more…

Schizophrenia is a complex disease whose biology is not completely understood, a reality that presents a major hurdle to companies developing new therapies for schizophrenia. more…

Overview Introduction Major Depressive Disorder (MDD) is estimated to affect over 34 million individuals yearly across the seven major markets. Only a fraction of this patient more…

Overview Introduction The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 2006-15 -6.0%). This will be primarily due more…

Overview Introduction Cognitive impairment is regarded as a core deficit of schizophrenia; the primary unmet need is the availability of an effective drug for the treatment of more…

more…

The new management report, Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US, examines the actions taken by more…

Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality. This more…

Overview of current market including profiles of key brands and key eventsimpacting each brand during 2003-2004 more…

Analysis of the prevalence of noncompliance in schizophrenia, bipolardisorder and depression with an overview of compliance improving strategies more…

This Frost & Sullivan research evaluates the current state of thepsychiatric therapeutics market and examines the key drivers and challenges thatshape its current and more…

This analysis is based on a survey of 180 prescribing physicians in the seven major markets as well as in-depth interviews with ADHD Key Opinion Leaders more…

This research from Frost & Sullivan evaluates the key trends in the U.S. insomnia therapies market. It offers comprehensive insights into the drivers and restraints affecting more…

This Frost & Sullivan research service evaluates the current and future prospects for atypical medications in the U.S. antipsychotic market in areas such as schizophrenia, more…

Fibromyalgia is a relatively common chronic pain syndrome, affecting around 2% of the population. This little understood market suffers from high unmet need both at the level more…

With the recent medical classification of adult ADHD and potentially twice the number of patients compared to pediatric ADHD, manufacturers are seeking new indications in this more…

Anxiety disorders are considered the most prevalent of psychiatric disorders, with a high incidence of comorbidity with other psychiatric disorders. more…

The bipolar disorder market is experiencing a renewed expansion in product life-cycle management. Presently, mood stabilizers are the basis of treatment, although the more…

The global antidepressant market has seen extraordinary growth over the last decade. However, with few entrants and a flood of patent expiries by 2009, the dynamics of this more…

The antipsychotic market is worth an estimated $10.7 billion and is led by Eli Lilly's blockbuster Zyprexa. After 2007, the market is expected to plateau due to the more…

Sleep disorders, such as insomnia, narcolepsy and restless leg syndrome, are becoming an increasing focus for pharmaceutical manufacturers. Sanofi-Synthlabo is testimony to more…

While the mild to moderate Alzheimer's disease (AD) market grew strongly over 2002 to exceed $1.5 billion, drug manufacturers are now recognizing opportunities in other areas more…

The objectives of the study are to present a comprehensive look at disorders that affect the mind. An overall discussion of mental health is presented along with an in-depth more…

Cymbalta (duloxetine) is a new antidepressant, marketed by Eli Lilly, set to launch into the major depression and stress urinary incontinence (SUI) markets in mid-2003. The more…

The treatment strategy of major depressive disorder (MDD) is changing. As primary care physicians gain more experience with antidepressants, referrals, principally to more…

Over the last decade, behavioral disorders have received increasing attention from the media and medical professionals, but only attention deficit / hyperactivity disorder more…

Currently, the ADHD market is dominated by methylphenidate (Ritalin and Concerta) and amphetamine (Adderall) based stimulants. However, in November 2002, Eli Lilly's Strattera more…

The growth of the antidepressant market over the last decade has been built upon increasingly sophisticated marketing strategies. This has not only made the depression market more…